EGRIFTA HC

Serial Number 88200427
602

Registration Progress

Application Filed
Nov 20, 2018
Under Examination
Approved for Publication
Published for Opposition
Registered

Basic Information

Serial Number
88200427
Filing Date
November 20, 2018
Abandonment Date
October 19, 2020
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Nov 9, 2020
Classes
005

Rights Holder

Theratechnologies Inc.

03
Address
2015 Peel Street
Suite 500
Montreal, Quebec H3A1T8
CA

Ownership History

Theratechnologies Inc.

Original Applicant
03
Montreal, Quebec CA

Legal Representation

Attorney
Jay A. Bondell, Esq.

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

20 events
Date Code Type Description
Nov 9, 2020 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Nov 9, 2020 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Nov 9, 2020 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 16, 2020 CNSI R SUSPENSION INQUIRY WRITTEN
Apr 16, 2020 GNSI S INQUIRY TO SUSPENSION E-MAILED
Apr 16, 2020 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 11, 2020 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 11, 2019 CNSL R SUSPENSION LETTER WRITTEN
Sep 11, 2019 GNSL S LETTER OF SUSPENSION E-MAILED
Sep 11, 2019 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 10, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 10, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 9, 2019 ALIE A ASSIGNED TO LIE
Sep 3, 2019 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 3, 2019 CNRT R NON-FINAL ACTION WRITTEN
Mar 3, 2019 GNRT F NON-FINAL ACTION E-MAILED
Mar 3, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 24, 2019 DOCK D ASSIGNED TO EXAMINER
Dec 8, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 23, 2018 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005